Considering SAINT Protocol for Depression? Ketamine Treatment & Spravato Explained

Can Ketamine or Esketamine (Spravato) Help If You're Considering the SAINT Protocol for Depression?

While the SAINT protocol offers a condensed, MRI-guided approach to TMS, esketamine (Spravato) and intramuscular (IM) ketamine therapy provide accessible, rapid-acting, evidence-based pharmacological options for adults navigating treatment-resistant depression.

The SAINT protocol is an accelerated, MRI-guided form of TMS that delivers 50 sessions over five days and showed a 79% remission rate in its original Stanford trial. It is exciting but extremely limited in availability and insurance coverage. If you are managing treatment-resistant depression, FDA-approved esketamine (Spravato) and evidence-based, off-label ketamine therapy offer a more accessible alternative available now.

If you've been reading about the SAINT protocol — formally known as Stanford Accelerated Intelligent Neuromodulation Therapy — you're likely someone who has already tried multiple treatments for depression and is evaluating what comes next. You may have tried two or more antidepressants targeting serotonin, norepinephrine, and dopamine without adequate relief. You may be weighing interventional options that work faster than traditional medications and through fundamentally different mechanisms.

This article is written for you. Not to tell you which treatment is "best" — that question doesn't have a universal answer — but to lay out what the clinical evidence actually says about SAINT, how it compares to off-label ketamine and esketamine (Spravato), and what factors might guide your decision.

What the SAINT Protocol Actually Involves

The SAINT protocol is not standard TMS. Conventional repetitive transcranial magnetic stimulation (rTMS) typically involves 30 to 36 sessions delivered over six weeks — a significant time commitment that can be difficult to sustain, particularly when depression makes daily functioning hard enough. SAINT condenses that entire course into five consecutive days, delivering approximately ten theta-burst stimulation sessions per day, with 50-minute rest intervals between sessions.

What makes SAINT distinct from earlier accelerated TMS protocols is its use of functional MRI (fMRI) to individually target the subgenual anterior cingulate cortex — a brain region implicated in mood regulation and the broader Default Mode Network. Rather than placing the magnetic coil using a generic scalp measurement (the "5 cm rule" used in older protocols), SAINT identifies the specific spot on an individual's left dorsolateral prefrontal cortex that shows the strongest functional connectivity to the subgenual cingulate. This individualized targeting is a meaningful advance.

The original Stanford study, published in 2020, reported a 79% remission rate among participants with treatment-resistant depression — a striking figure in a field where remission rates for third- or fourth-line treatments often hover between 10% and 30%. These results generated significant media coverage and legitimate clinical interest.

Why SAINT Has Limitations You Should Understand

The clinical results from the Stanford trial are genuinely exciting. But the gap between a landmark pilot study and a treatment you can actually access is wide — and if you are reading this, that gap matters right now.

• Availability is extremely limited. SAINT is currently offered at a small number of academic medical centers. It is not available at community mental health practices, and most TMS centers do not have the fMRI capability or clinical infrastructure to deliver this specific protocol.
• Insurance coverage is sparse. Most commercial insurers do not yet cover SAINT specifically. Some may cover the underlying TMS procedure codes, but the accelerated format and fMRI-guided targeting often fall outside standard authorization pathways. Out-of-pocket costs can run into the tens of thousands of dollars.
• Sample sizes remain small. The original Stanford study enrolled 29 participants. Larger, multi-site replication trials are underway, but the evidence base is still maturing. A 79% remission rate in a small, carefully selected academic sample may not generalize to broader clinical populations.
• It is non-pharmacological — which is both a strength and a constraint. SAINT does not involve any medication, which appeals to those who are wary of pharmacological side effects. However, it also means it does not engage the glutamate system or the BDNF-driven neuroplasticity pathways that pharmacological treatments like ketamine and esketamine (Spravato) directly modulate.

None of this diminishes SAINT's potential. It simply means that if you are evaluating your options today — particularly if you need relief within the coming weeks — SAINT may not yet be a practical choice.

How Ketamine and Esketamine (Spravato) Work Through a Different Mechanism

Where SAINT uses electromagnetic pulses to alter neural firing patterns from outside the skull, ketamine therapy and esketamine (Spravato) work pharmacologically — from the inside. The distinction is not just procedural; it is mechanistic. Off-label ketamine is a racemic mixture containing both the S-ketamine and R-ketamine molecules. Esketamine (Spravato) is the S-enantiomer (the "s" stands for sinistrum, Latin for "left", as the esketamine molecule is oriented to the left) and is the more active component.

Both modulate the glutamate system — the brain's primary excitatory neurotransmitter network. This is an entirely different pathway from the monoamine systems (serotonin, norepinephrine, and dopamine) targeted by SSRIs, SNRIs, and other traditional antidepressants. Through NMDA receptor blockade, these medications trigger a cascade that includes the release of Brain-Derived Neurotrophic Factor (BDNF), which acts as a growth signal for brain cells — encouraging them to reach out and form new synaptic connections.

"Ketamine induces the release of Brain-Derived Neurotrophic Factor, or BDNF, which acts as a growth hormone for the brain. Just as growth hormones in muscles cause hypertrophy and strength, BDNF enables brain cells to reach out and create new connections."

— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health

This neuroplasticity effect has a practical clinical translation: in the 48 to 72 hours following a session, the brain appears to be in a more receptive state. Paired with psychotherapy or your own self-guided practice, this window allows you to form new patterns of thought and behavior that depression had previously made rigid. The Default Mode Network, which in depression tends to become overactive and locked into cycles of rumination and negative self-referential thinking, is temporarily quieted. As it reorganizes, it may do so with less of the rigid, hopeless patterning that characterized the depressed state.

People with histories of substance dependence — opioid or other — should speak with providers about where they are in recovery. It can help cue the provider to your specific needs and help us deliver care safely.

A systematic review and meta-analysis comparing racemic ketamine and esketamine confirmed meaningful efficacy across both formulations, with the evidence base growing steadily over more than two decades of clinical research.

Comparing Accessibility: SAINT vs. Esketamine (Spravato)

If you need a rapid-acting treatment and want something available now — not in a future clinical trial — the practical differences between SAINT and esketamine (Spravato) are significant.

• FDA approval: Esketamine (Spravato) is FDA-approved for adults with treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant. SAINT does not have a separate FDA clearance; it uses FDA-cleared TMS devices but in an off-protocol manner at most sites. (Note: Intramuscular ketamine is an evidence-based, off-label application of a medicine that's been in use for over 50 years).
• Insurance coverage: Esketamine (Spravato) is covered by most major commercial insurers in Massachusetts. Accepted plans at Lumin Health include Aetna, Anthem, Blue Cross Blue Shield, Cigna, Evernorth, Mass General Brigham Health Plan, Harvard Pilgrim, Optum, Point32Health, United Healthcare, and Medicare. With insurance, the cost typically aligns with a standard office visit co-pay. By contrast, most commercial insurers do not cover off-label intramuscular (IM) ketamine therapy for mental health; sessions cost $500, though Lumin Health provides a Superbill for potential out-of-network reimbursement. SAINT often requires full out-of-pocket payment, sometimes reaching tens of thousands of dollars.
• Availability: Esketamine (Spravato) is available through REMS-certified centers across the country. Lumin Health, based out of the Boston Metro area and expanding to other states, is one such center with academically-affiliated providers specifically trained in ketamine and esketamine administration. SAINT remains confined to a handful of academic institutions.
• Treatment timeline: Both SAINT and esketamine (Spravato) are rapid-acting relative to traditional antidepressants. SAINT delivers its full course in five days. The induction phase for esketamine (Spravato) involves twice-weekly sessions for four weeks, transitioning to weekly and then biweekly maintenance. Many patients notice meaningful shifts within the first one to two weeks of esketamine (Spravato) treatment.
• Side effect profiles: SAINT's primary side effects relate to scalp discomfort and headache during stimulation. Common side effects of esketamine (Spravato) and ketamine include temporary dissociation, dizziness, nausea, and transient blood pressure elevation — all monitored during a mandatory two-hour observation period. Notably, neither treatment carries the memory-related side effects associated with electroconvulsive therapy (ECT), a distinction that matters to many people evaluating interventional options.

A post-approval review of esketamine five years after FDA clearance underscored its continued real-world efficacy and the expanding evidence base supporting its use in clinical settings beyond the original trials.

When SAINT Might Be Preferred

There are specific clinical scenarios where SAINT — if accessible — may be a particularly strong fit:

• If you cannot tolerate pharmacological treatments due to medication sensitivities, drug interactions, or personal preference for non-pharmacological interventions.
• If you have not responded to ketamine treatment or esketamine (Spravato) and are seeking a mechanistically different approach. Because SAINT works through electromagnetic neuromodulation rather than glutamate pathways, it may engage different circuits.
• If you have access to an academic center offering the protocol and the financial capacity to cover treatment out of pocket. Geographic proximity and insurance reality are not trivial factors — they shape what is actually feasible.
• If you are seeking an ultra-compressed treatment timeline. Five days is faster than any other interventional depression treatment currently available, which may suit specific life circumstances.

When Esketamine (Spravato) or Ketamine Therapy May Be Preferred

If you are managing treatment-resistant depression, the calculus often tips toward ketamine or esketamine (Spravato) for reasons that are both clinical and practical:

• When insurance coverage matters. Depression already carries enormous financial burden. A treatment that is covered by your insurer and costs a co-pay rather than thousands of dollars out of pocket may be the difference between starting treatment this month and waiting indefinitely.
• When you need something available now. Waitlists for SAINT at academic centers can stretch months. Lumin Health can typically begin treatment within about two weeks of initial contact.
• When glutamate-pathway engagement is clinically indicated. If your depression involves deeply entrenched negative thought patterns or rigid Default Mode Network activity, the pharmacological mechanism of ketamine — engaging glutamate and BDNF — offers a targeted biological intervention that TMS does not replicate.
• When ongoing maintenance is part of the plan. Depression is frequently recurrent. The structured maintenance phase of esketamine (Spravato) provides a framework for sustained care. SAINT does not yet have an established maintenance protocol.
• When the experiential component has therapeutic value. Ketamine therapy creates a temporary shift in perception that many describe as meaningful — a window in which old narratives loosen their grip and new perspectives become available. This is not a side effect; for many, it is part of the therapeutic process when combined with self-guided intent.

"The Default Mode Network is responsible for self-referential thinking. In depression, the DMN overvalues negative interpretations of neutral stimuli. While ketamine is in the system, the DMN ceases to be as networked — this freedom from classic interpretation allows patients to see old truths as mere products of perspective."

— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health

They Are Not Competitors — They Are Different Tools

The most important framing for anyone evaluating SAINT and ketamine therapy is this: these are mechanistically distinct treatments that serve overlapping but not identical populations. One uses electromagnetic fields to alter firing patterns in targeted cortical regions. The other uses pharmacology to shift glutamate signaling, promote synaptic growth, and temporarily restructure how the brain processes self-referential information.

Neither is universally superior. Someone who achieves relief with SAINT may not have responded to esketamine (Spravato), and vice versa. You might do well on ketamine treatment and not need SAINT, or if ketamine is contraindicated for you, you might be an ideal SAINT candidate.

What matters is that you — and your care team — have an honest, informed conversation about what is available, affordable, and clinically appropriate for your specific situation. If you are close to a Lumin Health practice, our academically-affiliated, psychiatrist-led team can help you evaluate these options clearly, including appropriate referrals for treatments we do not directly provide.

Frequently Asked Questions

Is the SAINT protocol FDA-approved?

SAINT uses FDA-cleared TMS devices, but the specific accelerated protocol does not have its own FDA approval. It is primarily available at select academic research centers, often as part of clinical trials or specialized programs.

Can I get SAINT and esketamine (Spravato) at the same time?

There is no established clinical guidance for combining these treatments simultaneously. They work through entirely different mechanisms — electromagnetic stimulation versus pharmacological glutamate modulation — so clinical decision-making determines which single pathway is appropriate.

How does ketamine therapy compare to standard TMS?

Standard rTMS typically requires 30 to 36 sessions over six weeks and targets prefrontal cortical activity. Ketamine therapy works pharmacologically through glutamate and BDNF pathways, often producing noticeable effects within days. Both are evidence-based; they engage different brain systems and may be appropriate for different clinical profiles.

Does Lumin Health offer TMS or the SAINT protocol?

No. Lumin Health specializes in FDA-approved esketamine (Spravato) and evidence-based, off-label intramuscular (IM) ketamine therapy. However, our psychiatrist-led team can help evaluate whether TMS, SAINT, or another intervention might be appropriate and can guide referrals to colleagues offering those treatments.

What if I've already tried ketamine and it didn't work?

Non-response to one treatment does not predict non-response to all treatments. If ketamine for depression was not effective, SAINT, ECT, or other interventional approaches may engage different neural circuits. Your brain isn't broken — it may just be stuck, and a personalized approach to treatment selection is increasingly supported by the research literature.

Exploring What May Be Right for You

If you are comparing interventional options for treatment-resistant depression — whether SAINT, esketamine (Spravato), ketamine therapy, ECT, or something else — the most important step is an honest clinical conversation about your specific history, your goals, and what is realistically accessible to you.

Lumin Health is based out of the Boston Metro area and expanding to other states. Our academically-affiliated providers are specifically trained in ketamine and esketamine and can help you think through whether these treatments may be a fit. We would be grateful to walk with you toward clarity, even if the right answer for you is something we don't directly offer.

If you'd like to explore whether esketamine (Spravato) or ketamine treatment may be appropriate for your situation, you can verify your insurance coverage or reach out to our team for a conversation. There is no pressure — only information, care, and options.

You've read the science. Now take the next step.

Lumin Health provides safe, expert-administered ketamine and Spravato treatment across Massachusetts and the greater Washington DC/Maryland area. Your journey starts with a free, no-commitment intro call.

Available in Massachusetts and the greater Washington DC/Maryland area.

Book a Free Intro Call